Tilray (NASDAQ:TLRY) released its earnings results on Tuesday. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02), Briefing.com reports. Tilray had a negative return on equity of 58.43% and a negative net margin of 157.05%. The business had revenue of $23.00 million during the quarter, compared to the consensus estimate of $20.50 million. The company’s quarterly revenue was up 194.9% on a year-over-year basis.
TLRY stock traded down $2.34 during trading hours on Wednesday, hitting $46.40. The company’s stock had a trading volume of 2,209,723 shares, compared to its average volume of 1,186,591. The company has a quick ratio of 20.75, a current ratio of 21.37 and a debt-to-equity ratio of 2.17. The company has a market capitalization of $4.50 billion and a price-to-earnings ratio of -56.59. Tilray has a 12 month low of $20.10 and a 12 month high of $300.00.
In other Tilray news, CFO Mark Castaneda sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $51.72, for a total value of $517,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Edward Wood Pastorius, Jr. sold 3,443 shares of the business’s stock in a transaction on Friday, April 5th. The stock was sold at an average price of $61.04, for a total transaction of $210,160.72. The disclosure for this sale can be found here. Insiders sold 196,109 shares of company stock valued at $12,522,598 over the last three months. Insiders own 3.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://dakotafinancialnews.com/2019/05/15/tilray-tlry-posts-earnings-results-misses-expectations-by-0-02-eps.html.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Story: What is systematic risk?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.